Description

DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG[1]. DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.–20°C (Powder, protect from light)-Applications-Cancer-programmed cell death-Formula-C72H79FN10O17-Citation–References-[1]Anish Thomas, et al. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254-e262.-CASNumber-2694856-51-2-MolecularWeight-1375.45-Compound Purity-99.34-SMILES-O=C1OCC2=C(C=C(C3=NC4=CC(F)=C(C)C(CC[C@@H]5NC(COCNC(CNC([C@H](CC6=CC=CC=C6)NC(CNC(CNC(CCOCCOCCOCCOCCNC(CCC(N7C8=CC=CC=C8C#CC9=CC=CC=C9C7)=O)=O)=O)=O)=O)=O)=O)=O)=C4C5=C3C)NC2=O)[C@]1(CC)O-Research_Area-Cancer-Solubility-DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)-Target-Drug-Linker Conjugates for ADC-Isoform-Traditional Cytotoxic Agents-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related